Premium
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment
Author(s) -
Shiran M. R.,
Chowdry J.,
RostamiHodjegan A.,
Ellis S. W.,
Lennard M. S.,
Iqbal M. Z.,
Lagundoye O.,
Seivewright N.,
Tucker G. T.
Publication year - 2003
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.2003.01851.x
Subject(s) - cyp2d6 , dextromethorphan , genotype , methadone , dextrorphan , pharmacology , medicine , pharmacogenetics , phenotype , methadone maintenance , biology , genetics , gene
Aims To assess CYP2D6 activity and genotype in a group of patients undergoing methadone maintenance treatment (MMT). Methods Blood samples from 34 MMT patients were genotyped by a polymerase chain reaction‐based method, and results were compared with CYP2D6 phenotype ( n = 28), as measured by the molar metabolic ratio (MR) of dextromethorphan (DEX)/dextrorphan (DOR) in plasma. Results Whereas 9% of patients (3/34) were poor metabolizers (PM) by genotype, 57% (16/28) were PM by phenotype ( P < 0.005). Eight patients, who were genotypically extensive metabolizers (EM), were assigned as PM by their phenotype. The number of CYP2D6 * 4 alleles and sex were significant determinants of CYP2D6 activity in MMT patients, whereas other covariates (methadone dose, age, weight) did not contribute to variation in CYP2D6 activity. Conclusions There was a discordance between genotype and in vivo CYP2D6 activity in MMT patients. This finding is consistent with inhibition of CYP2D6 activity by methadone and may have implications for the safety and efficacy of other CYP2D6 substrates taken by MMT patients.